Glumac N, Snoj M, Hocevar M, Novakovic S
Department of Tumor Biology, Institute of Oncology, 1000 Ljubljana, Slovenia.
Neoplasma. 2006;53(1):9-14.
The aim of this study was to evaluate the role of tyrosinase mRNA appearance in blood of malignant melanoma (MM) patients, especially with advanced stages, for predicting the disease progression, and consequently the survival. The tyrosinase mRNA was measured by nested RT-PCR in peripheral venous blood samples obtained from 86 patients (53 male and 33 female) with mainly stage III and IV MM. The data were analyzed using standard methods for survival analysis and logistic regression. Tyrosinase was negative in the MM patients with the disease stage I or II, positive tyrosinase was in 11/50 patients with stage III and in 5/22 patients with stage IV. Systemic metastases developed in 14/16 patients with positive tyrosinase and in 41/70 with negative tyrosinase. The 3-year survival was 8% and 28% among the patients with positive and the patients with negative tyrosinase, respectively. The log rank test showed statistically significant better survival of tyrosinase negative patients when compared to tyrosinase positive patients (p=0.039). Multivariate analysis using logistic regression indicated tyrosinase to be a statistically significant prognostic factor for the survival of MM patients after controlling for Breslow and ulceration values (p=0.006). Positive tyrosinase in peripheral venous blood is statistically significant, and more importantly independent negative predictor of survival.
本研究旨在评估酪氨酸酶mRNA在恶性黑色素瘤（MM）患者血液中，尤其是晚期患者血液中的出现情况，以预测疾病进展及患者生存情况。通过巢式逆转录聚合酶链反应（nested RT-PCR）检测了86例主要为III期和IV期MM患者（53例男性和33例女性）外周静脉血样本中的酪氨酸酶mRNA。采用标准的生存分析和逻辑回归方法对数据进行分析。I期或II期MM患者的酪氨酸酶呈阴性，III期患者中有11/50酪氨酸酶呈阳性，IV期患者中有5/22酪氨酸酶呈阳性。酪氨酸酶阳性的16例患者中有14例发生了全身转移，酪氨酸酶阴性的70例患者中有41例发生了全身转移。酪氨酸酶阳性患者和阴性患者的3年生存率分别为8%和28%。对数秩检验显示，与酪氨酸酶阳性患者相比，酪氨酸酶阴性患者的生存率在统计学上有显著提高（p=0.039）。使用逻辑回归进行的多因素分析表明，在控制了 Breslow 和溃疡值后，酪氨酸酶是MM患者生存的统计学显著预后因素（p=0.006）。外周静脉血中酪氨酸酶阳性具有统计学意义，更重要的是，它是生存的独立负性预测指标。
